Who are Comparator: lovastatin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Crestor, Lipitor, FLUVASTATIN SODIUM, Lescol, Continue Ritonavir-boosted PI+Rosuvastatin, Simvastatin (Zocor).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/comparator-lovastatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Comparator: lovastatin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparator: lovastatin (Comparator: lovastatin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Statin (HMG-CoA reductase inhibitor). Area: Cardiovascular.

phase 3 Statin (HMG-CoA reductase inhibitor) HMG-CoA reductase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Comparator: lovastatin (Comparator: lovastatin) — Organon and Co. Lovastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Comparator: lovastatin TARGET	Comparator: lovastatin	Organon and Co	phase 3	Statin (HMG-CoA reductase inhibitor)	HMG-CoA reductase
Crestor	rosuvastatin	AstraZeneca	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	2003-01-01
Lipitor	atorvastatin	Pfizer Inc.	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	1996-12-17
FLUVASTATIN SODIUM	FLUVASTATIN SODIUM		marketed		HMG-CoA reductase	1993-01-01
Lescol	FLUVASTATIN	Novartis	marketed	HMG-CoA Reductase Inhibitor	HMG-CoA reductase	1993-01-01
Continue Ritonavir-boosted PI+Rosuvastatin	Continue Ritonavir-boosted PI+Rosuvastatin	Juan A. Arnaiz	marketed	Antiretroviral combination (protease inhibitor + statin)	HIV protease (PI component); HMG-CoA reductase (rosuvastatin component)
Simvastatin (Zocor)	Simvastatin (Zocor)	New York State Psychiatric Institute	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2037-06-07 — Lipitor · 11654106 · US
2037-06-07 — Lipitor · 11369567 · US

Sponsor landscape (Statin (HMG-CoA reductase inhibitor) class)

Organon and Co · 2 drugs in this class
AstraZeneca · 1 drug in this class
Mitsukoshi Health and Welfare Foundation · 1 drug in this class
National Taiwan University Hospital · 1 drug in this class
Shenyang Northern Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Comparator: lovastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/comparator-lovastatin. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing